Publication | Open Access

Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo

NanomedicineSubcutaneous DeliveryAdvanced Breast CancerOncologyDrug TargetingNanoconjugated DoxorubicinPolymer-drug ConjugateMedicineBreast CancerTumor TargetingNano-drug DeliveryPharmacologyRadiation Oncology